The fibrinolytic activity in the N-butyl-N-butanol (4)-nitrosamine (BBN) induced bladder tumors in rats and normal rat bladders was investigated at cellular level by the histochemical fibrin slide technique, and the ratio of plasminogen activator and urokinase inhibitor contained in tissue was estimated by the fibrin plate method. The plasminogen activator activity in the bladder epithelium gradually decreased as the neoplastic process became established, and the cancer cells lost the fibrinolytic activity of the normal tissue from which they sprang. The ratio in the cancerous tissue was strikingly on the side of inhibitor (1:434) as compared with that in the normal tissue (1: 32). Concomitantly, a highly significant reduction of fibrinolytic activity in blood, assayed by euglobulin lysis time, was observed after the development of the carcinoma. It may be reasonable to assume that the ratio in the cancerous tissue serve for antiplasmin in the fibrinolytic system in blood. Antifibrinolysis induced with tranexamic acid had no significant effect on the incidence and growth of the bladder tumors.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
O'Meara, R. A. Q.: Coagulative properties of cancer. Irish J. Med. Sci. 6, 474 (1958)
O'Meara, R. A. Q.: Fibrin formation and tumor growth. Thromb. Diath. Haemorrh. (Suppl.) 28, 137 (1968)
Kreisler, L.: Effect of heparin on the growth of a transplantable lymphosacroma in mice. Science 115, 145 (1952)
Druckrey, H., Preussmann, R., Ivankovic, S., Schmidt, C. H., Mennel, H. D., Stahl, K. W.: Selective Erzeugung von Blasenkrebs an Ratten durch Dibuyl und N-Butyl-butanol (4)-nitrosamin. Z. Krebsforsch. 66, 280 (1964)
Ishikawa, M., Okajima, E., Imoto, T., Hiramatsu, T., Ito, N., Konishi, Y., Hiasa, Y.: Experimental studies on urinary bladder tumors. On the development of urinary bladder tumor in rats induced by N-Butyl-N-Butanol (4)-nitrosamine. Jap. J. Urol. 60, 99 (1969)
Tympanidis, K., Astrup, T.: Fibrinolytic activity of epithelium of bladder of rat and man. J. Urol. 105, 214 (1971)
Hisazumi, H., Naito, K., Misaki, T.: Fibrinolytic activity in normal and cancerous tissues of the bladder, Invest. Urol. 11, 28 (1973)
Sugiura, H.: Histochemical studies of cellular plasminogen activator. Jap. J. Urol. 64, 265 (1973)
Todd, A. S.: The histochemical localization of fibrinolytic activator. J. Path. Bact. 78, 281 (1959)
Hisazumi, H.: Inhibitory effect of normal and cancerous tissues of the bladder on plasminogen activation. (in press):
Astrup, T., Müllertz, S.: The fibrin plate method for estimating fibrinolytic activity. Arch. Biochem. 40, 346 (1952)
Deutsch, D. C., Mertz, E. T.: Plasminogen purification from human plasma by affinity chromatography. Science. 170, 1095 (1970)
von Kaula, K. N., Schultz, R. L.: Methods for the evaluation of human fibrinolysis. Amer. J. clin. Pathol. 29, 104 (1958)
Funahara, Y., Mihara, H., Kinjo, K.: Studies on the fibrinolysis in tumor bearing mice. III. Demonstration of the plasminogen activator in Ehrlich ascites tumor cells. Kobe J. med. Sci. 11, 73 (1965)
Kawano, T., Morimoto, K., Uemura, Y.: Urokinase inhibitor in human placenta. Nature 217, 253 (1968)
Brakman, P., Astrup, T.: Selective inhibitor in human pregnancy blood of urokinase induced fibrinolysis. Scand. J. clin. lab. Invest. 15, 603 (1963)
Worowski, K., Farbiszewski, R.: On the proteolytic enzyme inhibitors in malignant neoplastic diseases. Pol. Med. J. 11, 502 (1972)
This investigation was supported, in part, by a grant (No. 757181) in aid for the Miscellaneous Scientific Research from the Education Ministry
About this article
Cite this article
Hisazumi, H., Fukushima, K. A study on fibrinolysis in experimental bladder tumors. Urol. Res. 1, 186–191 (1973). https://doi.org/10.1007/BF00256622
- Experimental bladder tumors
- urokinase inhibitor
- tranexamic acid